A phase II trial of recombinant MAGE-A3 protein with immunostimulant AS15 in combination with high-dose Interleukin-2 (HDIL2) induction therapy in metastatic melanoma

BACKGROUND: HDIL-2 is approved for advanced melanoma based on its durable antitumor activity. MAGE-A3 cancer immunotherapeutic (MAGE-A3 CI) is a recombinant MAGE-A3 protein combined with an immunostimulant adjuvant system and has shown antitumor activity in melanoma. We assessed the safety and anti-...

Descripción completa

Detalles Bibliográficos
Autores principales: McQuade, Jennifer L., Homsi, Jade, Torres-Cabala, Carlos A., Bassett, Roland, Popuri, Rashmi Murthy, James, Marihella L., Vence, Luis M., Hwu, Wen-Jen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6300080/
https://www.ncbi.nlm.nih.gov/pubmed/30567529
http://dx.doi.org/10.1186/s12885-018-5193-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6300080/
https://www.ncbi.nlm.nih.gov/pubmed/30567529
http://dx.doi.org/10.1186/s12885-018-5193-9

Ejemplares similares